Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A top Marine shares his secrets to keeping fit at 50 - 2Woman charged in unprovoked stabbing of tourist changing baby's diaper in Macy’s Herald Square store
- 3Practice environmental safety in Style: Divulging Famous Electric Vehicle Brands
- 4Data centers in space: Will 2027 really be the year AI goes to orbit?
- 5'Zootopia 2' movie reviews: A heartwarming, hysterical and earnest 'ode to community'
- Remote Work Survival manual: Helping Efficiency at Home
- 7 Heavenly Espressos, One Do You Like?
- January full moon wows skywatchers with a striking 'Wolf Supermoon' (photos)
- Step by step instructions to Guarantee Your Internet Promoting Degree Supplements Your Profession Objectives
- 'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
- This Week In Space podcast: Episode 188 — A New NASA Leader Rises?
- 10 Hints for an Effective New employee screening
- Kansas school officials report high student illness, dismiss early
- Have gravitational waves provided the first hint of primordial black holes born during the Big Bang?
